Bilcare Limitedhas informed the Exchange about the outcome of Board Meeting.

Bilcare Limited Tel +91 20 6600 7559 direct. bi l@bilcare.com B ilcare 301 Kamal l<unj www.bilcare-group.com 'Re,s-ea.,rdv 8 Shlvajl Housing Society Pune 411 016 India Date: 13 August 2026 BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 526853 Sub: Outcome of Board Meeting Dear Sir/Madam, Pursuant to Regulation 30 read with Schedule III of the SEBI LODR Regulations, we hereby inform you that the Board of Directors, at its meeting held on 13 August 2026, has approved the following: A. Unaudited Financial Results for the quarter ended June 30, 2026 Pursuant to Regulation 33 of the SEBI LODR Regulations, we are enclosing herewith the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026, together with the Limited Review Report issued by the Statutory Auditors of the Company. The aforesaid financial results were duly considered and approved by the Board of Directors of the Company at its meeting held on August 13, 2026. B. Changes in Directors • Appointment of Mr. Mohan Bhandari as an Executive Director of the Company, with effect from August 13, 2026, subject to the approval of the Members in the ensuing General Meeting of the Company. The requisite disclosure as prescribed under the SEBI LODR Regulations is enclosed herewith as Annexure A. • Reappointment of Ms. Kavita Bhansali as Executive Director for a further term of five years, subject to the approval of the Members in the ensuing General Meeting of the Company. The requisite disclosure as prescribed under the SEBI LODR Regulations is enclosed herewith as Annexure B. C. Changes in Key Managerial Personnel - Resignation and Appointment of Company Secretary a. Mr. Sagar R. Baheti, Company Secretary, Compliance Officer and Key Managerial Personnel of the Company, has tendered his resignation from the position of Company Secretary and Compliance Officer on August 13, 2026. b. The Board of Directors has approved the appointment of Mr. Mayur Dave, Company Secretary, Compliance Officer and Key Managerial Personnel of the Company. The requisite disclosure as prescribed under the SEBI LODR Regulations is enclosed herewith as Annexure C. D. Voluntary winding up of Bilcare INC The proposal of voluntary winding up of Bilcare INC, a wholly owned subsidiary of the Company in United States of America, as per the applicable laws of United States of America. The said subsidiary is not a material subsidiary of the Company. Regd Office 1028 Shiroli Rajgurunagar Pune 410 505 India Tel: +91 2135 647501 CIN: L28939PN1987PLC043953 • GST: 27AABCB2242F1Z6 Bilcare Limited Tel +91 20 6600 7559 direct. bil@bilcare.com Bilcare 301 Kamal Kunj www.bilcare-group.com 8 Shivaji Housing Society 'R.e5-earcl-v Pune 411 016 India The requisite disclosure as prescribed under the SEBI LODR Regulations is enclosed herewith as Annexure D. The Board meeting commenced at 04:30 P.M. and concluded at 08:30 P.M. (1ST). You are requested to take the same on record and confirm receipt of the same. Thanking you, Yours faithfully, For Bilcare Limited Sagar R. Baheti Company Secretary Encl: as above Regd Office 1028 Shiroli Rajgurunagar Pune 410 505 India Tel: +91 2135 647501 CIN: L28939PN1987PLC043953 " GST: 27AABCB2242F1Z6 Bilcare Limited Registered Office: 1028, Shiroli, Pune 410 505. Tel : +91 2135 647300 Fax : +91 2135 224068 Email: cs@bilcare.com Website: www.bilcare-group.com CIN : L28939PN1987PLC043953 A. Quarterly Integrated Filing (Financials) Standalone Unaudited Financial Results for the quarter ended 30 June 2026 ('{ in Crores) Quarter ended Year ended Sr.No. Particulars 30 June 31 March 30 June 31 March 2026 2026 2025 2026 (Unaudited) (Audited) (Unaudited) (Audited) 1. Income Revenue from operations 1.94 1.20 2.07 6.85 Other Income 4.36 3.82 6.72 19.53 Total income 6.30 5.02 8.79 26.38 2. Expenses a. Cost of materials consumed 0.53 0.12 0.67 1.77 b. Changes in inventories of finished goods, work-in-progress and stock-in-trade c. Employee benefits expense 1.20 0.78 1.29 4.87 d. Finance costs 0.12 0.14 0.14 0.60 e. Depreciation and amortisation expense 0.60 0.61 0.68 2.72 f. Other expenses 1.20 8.28 1.52 12.70 Total expenses 3.65 9.93 4.30 22.66 3. Profit/ (Loss) before tax and exceptional items (1-2) 2.65 (4.91) 4.49 3.72 4. Exceptional items (1.74) (2.08) (2.16) 5. Profit/ (Loss) before tax (3 + 4) 0.91 (6.99) 4.49 1.56 6. Tax expense (0.13) (0.64) 0.90 0.57 (i) Current tax (ii) Adjustment of tax relating to earlier years (iii) Deferred tax (0.13) (0.64) 0.90 0.57 7. Net Profit/ (Loss) for the period (5-6) 1.04 (6.35) 3.59 0.99 8. Other comprehensive income A (i) Items that will not be reclassified to profit or loss (0.03) 0.23 0.37 (ii) Income tax relating to items that will not be reclassified to profit or loss 0.01 (0.13) (0.13) B (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss Other comprehensive income, net of taxes (0.02) 0.10 0.24 9. Total comprehensive income (7+8) 1.02 (6.25) 3.59 1.23 10. Paid-up Equity Share Capital (face value Rs.10/-each) 23.55 23.55 23.55 23.55 11. Reserves i.e. Other equity 397.34 12. Earnings Per Share ( EPS) ( Face value Rs. 10/-per share) a Basic EPS 0.44 (2.70) 1.52 0.42 b Diluted EPS 0.44 (2.70) 1.52 0.42 Bilcare Limited Registered Office: 1028, Shiroli, Pune 410 SOS. Tel : +91 2135 647300 Fax : +91 2135 224068 Email : cs@bilcare.com Website: www.bilcare-group.com CIN : L28939PN1987PLC043953 Standalone Notes: 1 The Company has only one reportable segment namely "Pharma Packaging Research Solutions". 2 The above results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of Companies Act, 2013 read with the relevant rules issued thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 3 The accounts are prepared on a going-concern basis given the positive prospects going forward, including Management's strategic plan for the foreseeable future, cash flow projection, and future business prospects for the GCS Business. 4 In respect of the public fixed deposit liability taken over by the cawihans India Limited (CIL) as per the Business Transfer Agreement (BTA), the statutory compliances is the responsibility of the Company. Further in line with the BTA, the additional interest for cumulative fixed deposits has been expensed as interest cost. The Company had received an order from Hon'ble National Company Law Tribunal Mumbai, dated 5th June 2026, directing Company to transfer the outstanding amount to the Investor Education Protection Fund (IEPF) on or before 15th July 2026. In accordance with the aforesaid order, the Company has complied with the directions contained therein, including the transfer of Rs. 2.93 crores (inclusive of Rs. 2.34 crores which is pertaining to Caprihans India Limited) to the IEPF maintained by the Government of India on 10th July 2026. 5 The land parcels against advance which were capitalized in FY 2023-24, is continued to be shown as "Asset Held for Sale" as at June 30, 2026 having a book value of Rs 64.07 crores. 6 The penal interest as per the agreement terms w.r.t. CSIR loan of Rs. 18.55 crores is considered under Contingent Liability. The matter is currently sub judice. 7 As on 31st March 2026, the company had option for conversion of 20,20,000 warrants, for which Rs.10.10 Crores had been paid as warrant subscription amount. During the quarter ended, June 2026 the company paid INR 25.58 Crores being 75% of the 17,05,000 outstanding warrants. Conversion option attached to 3,15,000 share warrants were not exercised. Hence the aforesaid warrants lapsed and the amount was forfeited. Impact of same has been considered under exceptional items. 8 The Company is under investigation by the SFIO pursuant to the MCA's order dated 3 June 2020. The Hon'ble Bombay High Court disposed of the exi [Showing first 8,000 characters — download PDF for full document]